

INDUSTRY UPDATE - 31 December 2024

VALUATION MULTIPLES

Forward EV / EBITDA Multiples (monthly to 30/11/2024) Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have remained the same over the period. At the end of November, the sector traded on a forward EV / EBITDA multiple of 9.6x, compared to the ASX200 on 9.2x.



Average Values and Trading Multiples (monthly to 30/11/2024) Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2025	EV/EBIT FY2025	Price / Earnings FY2025
Aged Care	1,926	15.9x	27.0x	40.2x
Biotech	156,987	5.5x	8.0x	27.2x
Hospitals & Clinics	44,187	8.8x	19.9x	83.2x
Medical Devices	20,442	18.8x	22.3x	34.4x
Healthcare		10.4x	18.9x	66.8x

Note: Multiples are based on the forward year of the reported period, which for the majority of companies in the sector is FY2025. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result.

¹ The InterFinancial Healthcare Index set is an unweighted index comprising Healthcare sector related companies trading on the Australian Securities Exchange (ASX). Estimates are sourced from FactSet Research Systems Inc.



INDUSTRY UPDATE - 31 December 2024

MERGER & ACQUISITION NEWS...



Value: \$229.8m

The ACCC has provide clearance for Australian medical imaging provider, **Integral Diagnostics**, to acquire local provider **Capitol Health Limited**.



Value: \$120m

Randlab Australia, an Australian equine product manufacturer has been acquired by U.K. based **Animalcare Group**, another veterinary pharmaceutical business. The transaction was reported at 10.9x EBITDA.



Value: Undisclosed

Australian aged care and retirement living provider, **Tingari Group**, has acquired **Cumberland Villages** from **Arton Group**, another Australian-based retirement living village. This transaction adds 3 living facilities to **Tingari Group's** portfolio.



Value: \$698.5m



Sonic Healthcare has entered into a binding agreement with Laboratory Group Dr.Kramer & Colleagues (LADR), a German laboratory network worth \$698.5m. In CY 2024 LADR's revenues will be ~€370m (~AUD 610m) with EBITDA (post AASB 16 Leases) of ~€50 million (~AUD 82 million). The agreed cash and debt free enterprise Value ('EV') for LADR is €423 million and will be satisfied by the issue of Sonic Healthcare ordinary shares to the sellers with a maximum value equivalent to ~€222 million, with the balance through cash. This corresponds to an EV/EBITDA of 8.5x EBITDA.



INDUSTRY UPDATE - 31 December 2024

UNDER THE MICROSCOPE...

- A recently passed aged-care bill is expected to drive a new round of strategic M&A. Bain Capital is considering selling aged
 care operator Estia Health. Additionally, Pacific Equity Partners is currently in talks to buy 50% of Opal. Regis Healthcare is
 currently being eyed by private equity investors as well.
- Marina Radiology, a Melbourne-based radiology business valued at AUD 170m, is seeking private equity or other buyers.
- Tender Loving Care (TLC) Disability Services, an Australian provider of healthcare services specialising in disability care, is
 mulling strategic investment options for its next growth phase
- Anteris Technologies Global Corp, announced that it has launched the roadshow for its proposed initial public offering of 14,800,000 shares of its common stock in the U.S.
- Visioneering Technologies, Inc, has submitted a formal request to the Australian Securities Exchange (ASX) to be removed from the official list of the ASX in accordance with ASX Listing Rule
- Pacific Equity Partners and Medibank are considered the most likely buyers for Plena, an Australia-based allied healthcare business, currently owned by Adamantem Capital.



INDUSTRY UPDATE - 31 December 2024

CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact Michael Kakanis

Name	Position	Email
Sharon Doyle	Executive Chair	sdoyle@interfinancial.com.au
Brad Shaw	CEO	bshaw@interfinancial.com.au
Mark Steinhardt	Executive Director - M&A	msteinhardt@interfinancial.com.au
Andrew Wheeler	Director	awheeler@interfinancial.com.au
Anuk Manchanda	Director	amanchanda@interfinancial.com.au
Shaun Conroy	Director - Growth Advisory	sconroy@interfinancial.com.au
Derek Thomson	Director - Clean Energy & ESG	dthomson@interfinancial.com.au
Cameron Hall	Director - Consulting & Advisory	chall@interfinancial.com.au
Michael Kakanis	Director	mkakanis@interfinancial.com.au
Jenny Zeng	Associate Director	jzeng@interfinancial.com.au
Lucy Clarke	Associate	lclarke@interfinancial.com.au
Tahlia Micallef	Associate	tmicallef@interfinancial.com.au
Nasia Christodoulou	Analyst	nchristodoulou@interfinancial.com.au

DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

Important Disclaimer – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

Disclosure. InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.

InterFinancial
Corporate Finance Limited
ABN: 49 136 962 966
AFGL: 341675
Level 2, 201 Charlotte Street
GPD Box 975
Brisbane Queensland 4001
[07] 3218 9100
adminisinterfinancial com.au
www.interfinancial.com.au

